Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Aminah Jatoi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1081-189X; OpenAlex author ID A5059012052. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 trial · 2017: 1 paper · 2018: none · 2019: none · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 2 papers

Papers 10

  1. Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment bur… Last author DOI 10.1007/s00262-023-03397-4↗
  2. A TGF-β/KLF10 signaling axis regulates atrophy-associated genes to induce muscle wasting in pancreatic cancer. Co-author DOI 10.1073/pnas.2215095120↗
  3. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  4. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  5. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  6. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  7. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  8. Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-17-0100↗
  9. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  10. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Co-author DOI 10.1097/cad.0000000000000009↗

Trials 1

  1. Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer Principal investigator NCT02671890↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gloria M. Petersen · 5 shared papers, 2017–2021 · strength 0.51
  2. Amit Mahipal · 3 shared papers, 2020–2021 · strength 0.34
  3. Lisa A. Boardman · 3 shared papers, 2017–2021 · strength 0.31
  4. Kari G. Rabe · 3 shared papers, 2017–2021 · strength 0.31
  5. Samuel O. Antwi · 3 shared papers, 2017–2021 · strength 0.31
  6. Ann L. Oberg · 3 shared papers, 2017–2021 · strength 0.31
  7. Tanios Bekaii‐Saab · 3 shared papers, 2020 · strength 0.28
  8. Robert R. McWilliams · 3 shared papers, 2020 · strength 0.28
  9. Michael Harrison Storandt · 1 shared paper, 2023 · strength 0.26
  10. Nguyen H. Tran · 1 shared paper, 2023 · strength 0.26
  11. Hugues Sicotte · 2 shared papers, 2020–2021 · strength 0.23
  12. Joleen Marie Hubbard · 2 shared papers, 2020 · strength 0.21
  13. John R. Ogden · 2 shared papers, 2020 · strength 0.21
  14. Hao Xie · 2 shared papers, 2020 · strength 0.21
  15. Wen Wee Ma · 2 shared papers, 2020 · strength 0.21
  16. Paige C. Arneson‐Wissink · 1 shared paper, 2023 · strength 0.18
  17. Aneesha Dasgupta · 1 shared paper, 2023 · strength 0.18
  18. Jason D. Doles · 1 shared paper, 2023 · strength 0.18
  19. Julian R. Molina · 2 shared papers, 2013–2020 · strength 0.12
  20. Charles Erlichman · 2 shared papers, 2013–2020 · strength 0.12
  21. Angela L. McCleary‐Wheeler · 2 shared papers, 2015–2020 · strength 0.11
  22. Martín E. Fernández-Zapico · 2 shared papers, 2015–2020 · strength 0.11
  23. Mark Joseph Truty · 1 shared paper, 2020 · strength 0.10
  24. Wilma Lingle · 1 shared paper, 2020 · strength 0.08
  25. Mitesh J. Borad · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.